Archive for July, 2009

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES REMAINS COMMITTED TO PROCUREMENT OF BIOTHRAX® UNDER CURRENT CONTRACT

ROCKVILLE, MD, November 19, 2007 —Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Department of Health and Human Services (HHS) has reaffirmed its commitment to continue to purchase BioThrax® (Anthrax Vaccine Adsorbed) under the current contract for 18.75 million doses that provides for a firm fixed price of $400 million plus an additional $34 [...]

Posted on July 30, 2009 at 5:58 am by admin · Permalink · Leave a comment
In: Uncategorized

EMERGENT BIOSOLUTIONS ANTICIPATES 2ND QUARTER BIOTHRAX REVENUES OF APPROXIMATELY $20 MILLION BASED ON ACCELERATED DELIVERY TO DEPARTMENT OF DEFENSE

ROCKVILLE, MD, June 27, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today that, pursuant to the terms of an amended contract with the U.S. Department of Defense (DoD), it anticipates completing delivery of 900,000 doses of BioThrax® (Anthrax Vaccine Adsorbed) during the quarter ending June 30, 2007 or shortly thereafter.  The company anticipates [...]

EMERGENT BIOSOLUTIONS ANNOUNCES EXPANSION OF BOARD OF DIRECTORS AND APPOINTMENT OF DR. SUE BAILEY TO THE COMPANY’S BOARD OF DIRECTORS

ROCKVILLE, MD, June 15, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today that at a regularly scheduled meeting of its board of directors the board passed a resolution authorizing the expansion of the total number of members of the board to eight.  The board also unanimously appointed Sue Bailey, M.D., as a Class [...]

EMERGENT BIOSOLUTIONS ANNOUNCES RESULTS FROM ANNUAL MEETING OF STOCKHOLDERS

ROCKVILLE, MD, June 14, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today the results of the company’s 2007 annual meeting of stockholders, which took place today at the Hyatt Regency Bethesda at 10:00 am Eastern.
There were present, in person or represented by proxy, the holders of more than a majority of the shares [...]

EMERGENT BIOSOLUTIONS ANNOUNCES DR. STEPHEN LOCKHART JOINS COMPANY TO LEAD COMMERCIAL PRODUCT DEVELOPMENT SUBSIDIARY

Dr. Lockhart Brings Top-Tier Pharma Leadership to Development of Company’s Commercial Product Portfolio
ROCKVILLE, MD, October 18, 2007—Emergent BioSolutions Inc. (NYSE: EBS) announced today that Dr. Stephen Lockhart has been appointed President, Emergent Product Development UK.  Dr. Lockhart will be based at the company’s office located in Wokingham, England, and his responsibilities will include providing [...]

STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE, JR., FORMER BOARD MEMBER.

ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of  Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral [...]

Emergent BioSolutions Anticipates 2nd Quarter BioThrax Revenues of Approximately $20 Million Based on Accelerated Delivery to Department of Defense.

Company Preparing Response to DoD Request for Proposal for Delivery of Up to 14 Million Additional Doses of BioThrax
ROCKVILLE, Md. — Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced today that, pursuant to the terms of an amended contract with the U.S. Departmentof Defense (DoD), it anticipates completing delivery of 900,000 doses of BioThrax([R]) (Anthrax [...]

Fuad El-Hibri Profiles

Fuad El-Hibri on backtype
Fuad El-Hibri on BigContact
Fuad El-Hibri on BlogCatalog
Fuad El-Hibri on Blogger
Fuad El-Hibri on BloggersUnite
Fuad El-Hibri on Carbonmade
Fuad El-Hibri on Disqus
Fuad El-Hibri on FriendFeed
Fuad El-Hibri on HelloTxt
Fuad El-Hibri on Identica
Fuad El-Hibri on isfingawesome
Fuad El-Hibri on koornk
Fuad El-Hibri on kwippy
Fuad El-Hibri on [...]

Posted on at 5:25 am by admin · Permalink · Leave a comment
In: Uncategorized · Tagged with: , , , ,

Emergent Biosolutions Submits Proposal In Response To Hhs’ Rfp For Development And Procurement Of A Recombinant Protective Antigen Anthrax Vaccine

The company’s submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and [...]

Emergent Biosolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology

Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product [...]